This trial is testing a new drug to see what dose is safe and effective.
3 Primary · 7 Secondary · Reporting Duration: Up to 1 year and 10 months
1 Treatment Group
1 of 1
160 Total Participants · 1 Treatment Group
Primary Treatment: JNJ-78278343 · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · Male Participants · 6 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is enrollment currently open for participation in this trial?
"As reported on clinicaltrials.gov, this research endeavour is in the process of sourcing participants. It was posted initially on July 13th 2021 and recently updated on November 22nd 2022." - Anonymous Online Contributor
What ultimate effects are investigators hoping to observe with this clinical investigation?
"The principal purpose of this prolonged (over one year and ten months) clinical trial is to determine the occurrence rate of dose-limiting toxicity. Secondary objectives involve measuring serum concentrations of anti-JNJ78278343 antibodies, prostate specific antigen levels, as well as calculating PSA response rates by evaluating any decline from baseline values that are greater than 50%." - Anonymous Online Contributor
How many participants have been recruited for this experiment?
"Affirmative. According to the clinicaltrials.gov, this medical study is actively recruiting subjects that meet the criteria it posted on July 13 2021 and updated on November 22 2022. The research project requires 110 patients from 3 sites for its completion." - Anonymous Online Contributor
What potential risks are posed by JNJ-78278343?
"Due to the limited supporting evidence for JNJ-78278343's efficacy and safety, our team at Power judged it a score 1 on the scale of 1 to 3." - Anonymous Online Contributor